Cingulate (NASDAQ:CING – Get Free Report) posted its quarterly earnings data on Friday. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.05), FiscalAI reports.
Cingulate Stock Performance
CING traded down $0.19 during trading on Friday, reaching $4.30. 188,350 shares of the company’s stock were exchanged, compared to its average volume of 132,153. Cingulate has a fifty-two week low of $3.16 and a fifty-two week high of $11.89. The firm has a market capitalization of $62.52 million, a PE ratio of -1.20 and a beta of -0.88. The company’s fifty day moving average price is $4.85 and its 200-day moving average price is $5.40.
Analysts Set New Price Targets
A number of brokerages have commented on CING. Weiss Ratings lowered Cingulate from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, November 3rd. Wall Street Zen cut Cingulate from a “hold” rating to a “sell” rating in a research note on Saturday, November 7th. Finally, Roth Capital set a $9.00 target price on Cingulate and gave the stock a “buy” rating in a research report on Sunday, August 23rd. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $27.00.
Get Our Latest Analysis on Cingulate
Cingulate Company Profile
Cingulate is a clinical-stage biopharmaceutical company developing prescription treatments for attention-deficit/hyperactivity disorder (ADHD). The company’s approach is to improve how existing medicines are delivered over the course of the day. Its lead candidate, CTx-1301, is an extended-release formulation of dexmethylphenidate designed to provide multiple timed releases of medication. Cingulate is also developing CTx-1302, another candidate for ADHD. The company uses its proprietary Precision Timed Release drug-delivery platform to develop these candidates.
Read More
- Five stocks we like better than Cingulate
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
- Is It Too Late to Buy the Dip? 3 Corners of the Market Still Offering Real Value
Receive News & Ratings for Cingulate Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cingulate and related companies with MarketBeat.com's FREE daily email newsletter.
